Last updated: July 18, 2026
Evofem Biosciences, Inc. sued Padagis Israel Pharmaceuticals Ltd. in the Eastern District of Virginia in 2023 under the Hatch-Waxman framework tied to Evofem’s AVTS? contraceptive product portfolio. The docket entry shown (1:23-cv-00606) identifies the matter as a patent/IP dispute but the case record required for a complete litigation summary, including asserted patents, Orange Book-listed drugs, Paragraph IV allegations, claim construction, settlement terms, and current posture, is not available in the provided information.
What happened in Evofem Biosciences v. Padagis Israel Pharmaceuticals Ltd 1:23-cv-00606?
No complete case-record details are available in the provided input to accurately state: the filing date, court division, asserted patent numbers, accused product label/ANDA/BLA references, the specific causes of action, or the relief requested.
What patents did Evofem assert in 1:23-cv-00606?
The patent list and asserted claims are not provided.
What product or regulatory filing did Padagis challenge in 1:23-cv-00606?
The accused product identity (drug name, dosage form, strength), and whether the infringement theories target an ANDA (including Paragraph IV), are not provided.
What procedural events occurred (motions, hearings, rulings)?
The docket milestones (service, preliminary injunction filings, Rule 12 motions, Markman schedules, discovery orders, claim construction, summary judgment, trial settings, or appellate activity) are not provided.
Which court handled 1:23-cv-00606 and what does the jurisdiction imply for Hatch-Waxman leverage?
The case citation supplied is insufficient to determine the specific adjudicating judge, division, scheduling posture, and the typical leverage effects (tempo for trial, injunction likelihood, and settlement probability) without the actual docket content.
Was this an ANDA Paragraph IV litigation or a different IP theory?
Not determinable from the provided information.
Was the case about method-of-use, formulation, or manufacturing patents?
Not determinable from the provided information.
When does the infringement claim turn on ANDA exclusivity timelines and patent expiration?
A timeline requires at least:
- the reference listed drug (RLD) name tied to Evofem’s Orange Book listings,
- the asserted patent expiration dates (and any pediatric exclusivity),
- the ANDA filing date and any relevant 30-month stay trigger,
- the Orange Book approval history,
none of which are included in the provided input.
What is the status of Evofem v. Padagis (pending, dismissed, settled, or judgment entered)?
The procedural status cannot be determined from the provided input.
Did the parties enter a settlement agreement?
No settlement text or docket outcome is provided.
Was there a consent judgment or stipulated dismissal?
No docket outcome is provided.
Has any injunction been issued or denied?
No order information is provided.
How strong is Evofem’s patent estate in this matter?
Strength analysis requires:
- the asserted patent family sizes and remaining term,
- cited prior art,
- prosecution history,
- claim scope versus the accused dosage form/route,
- validity defenses actually raised,
none of which are available in the provided input.
What Paragraph IV challenges and generic entry risks exist for Evofem’s product in light of this case?
A generic launch risk assessment requires:
- which generic/ANDA is involved,
- whether liability was found,
- whether a 30-month stay expired,
- whether a settlement occurred and with what launch dates,
none of which are available.
How does Evofem’s litigation position compare with other AVTS-related Hatch-Waxman disputes?
No comparative dataset or related case set is provided.
What Orange Book status and FDA pathway facts govern the dispute?
Orange Book listings and FDA approval status are not provided, so this section cannot be completed.
Key Takeaways
- The docket identifier (Evofem Biosciences, Inc. v. Padagis Israel Pharmaceuticals Ltd., 1:23-cv-00606) confirms a filed dispute, but the provided information does not include the required case-record facts to summarize asserted patents, regulatory linkage, procedural milestones, or current posture.
- No actionable litigation details (claim list, infringement theories, validity arguments, outcomes, or settlement terms) can be produced from the input provided.
FAQs
- What patents are asserted in Evofem v. Padagis 1:23-cv-00606?
- Is 1:23-cv-00606 tied to a Paragraph IV ANDA and what RLD does it reference?
- What procedural step is the case at (motion to dismiss, Markman, summary judgment, trial)?
- Has Evofem and Padagis entered a settlement and what launch dates result?
- What is the remaining patent and exclusivity term exposure for the relevant Evofem product(s) in the U.S.?
References
No sources were provided or cited in the input to support a litigation summary.
